ARXT Adams Respiratory Therapeutics (MM)

NEW YORK, Jan. 29 /PRNewswire/ -- QED International Associates, Inc, administrator for the HealthShares(TM) Indexes, a series of 20 underlying indexes for the HealthShares(TM) Exchange-Traded Funds, today announced that effective at the opening of trading on Thursday January 31, 2008 KV Pharmaceutical Company (NYSE:KV-A) will replace Adams Respiratory Therapeutics (NASDAQ:ARXT) in the HealthShares(TM) Composite Index. Watson Pharmaceuticals Inc. (NYSE:WPI) will also replace Adams Respiratory Therapeutics in the HealthShares(TM) Respiratory/Pulmonary Index. Adams Respiratory Therapeutics is being acquired by Reckitt Benckiser Group PLC (London Stock Exchange: RB.L) The HealthShares(TM) Composite Index consists of the 80 largest companies by market capitalization that are engaged in healthcare, life sciences and/or biotechnology that are part of the 20 Composite eligible Indexes. Companies included in the HealthShares(TM) Respiratory/Pulmonary Index are engaged in the research, development, and/or commercialization of therapeutic agents treating various respiratory and/or pulmonary diseases including, but not limited to, asthma, chronic obstructive pulmonary disease, emphysema, tuberculosis and pulmonary arterial hypertension. About QED International Associates QED International, based in New York, is a leading financial industry consulting firm specializing in quantitative modeling and the design, development and maintenance of indexes and Exchange Traded Funds. For more information, visit the company's website at http://www.qedinternational.com/ DATASOURCE: QED International Associates, Inc CONTACT: Ed Matluck, CEO, or Michael Carty, Senior Advisor, +1-212-953-4058, both for QED International Web site: http://www.qedinternational.com/

Copyright